
    
      STUDY OBJECTIVE - To compare water vapor thermotherapy with the REZŪM™ System to dual drug
      therapy for the treatment of symptomatic benign prostatic hyperplasia refractory to
      alpha-blocker monotherapy in sexually active men.

      STUDY DESIGN - Multicenter open-label randomized controlled parallel-group post-market trial.

      STUDY TREATMENTS AND RANDOMIZATION - Subjects will be randomly assigned to REZŪM or dual drug
      therapy treatments; 1:1 randomization via the electronic data capture (EDC) system. Both
      treatments are commercially available. Subjects randomized to receive the REZŪM treatment
      will receive standardized treatment and subjects randomized to dual drug therapy will receive
      the local formulary preferred choice of urinary selective alpha blocker and 5-alpha reductase
      inhibitor.

      VISIT SCHEDULE - Study visits are at: enrollment/baseline, treatment, 3 months, 6 months, and
      yearly follow-up through 2 years.
    
  